TABLE 8.
Retrospective Lyme positive non-U.S. cohorta
| Test kit | No. of samples |
PPA | 95% CI | P | ||
|---|---|---|---|---|---|---|
| Pos | Equ | Neg | ||||
| BioPlex 2200 Lyme Total | 76 | 2 | 25 | 75.7 | 66.6–83.0 | Ref |
| Immunetics Lyme C6 | 66 | 3 | 34 | 67.0 | 57.4–75.3 | 0.049 |
| Zeus Borrelia VlsE1/pepC10 | 57 | 6 | 40 | 61.2 | 51.5–70.0 | <0.001 |
| DiaSorin LIAISON Borrelia (lgM+IgG) | 65 | 5 | 33 | 68.0 | 58.4–76.2 | 0.077 |
| DiaSorin LIAISON Borrelia IgM II | 49 | 3 | 51 | 50.5 | 41.0–60.0 | <0.001 |
| DiaSorin LIAISON Borrelia IgG | 45 | 7 | 51 | 50.5 | 41.0–60.0 | <0.001 |
a
Vendor-tested Lyme disease-positive patient sera (n = 103) collected from an area of endemicity within Ukraine were assessed for reactivity to commercially available Lyme test kits. All sera were characterized by the vendor as “early-stage” Lyme infections (EM rash positive). PPA, positive percent agreement; 95% CI, 95% confidence interval; Ref, reference.